BR0007500A - Composto triazol, fármaco, e, uso do composto - Google Patents

Composto triazol, fármaco, e, uso do composto

Info

Publication number
BR0007500A
BR0007500A BR0007500-0A BR0007500A BR0007500A BR 0007500 A BR0007500 A BR 0007500A BR 0007500 A BR0007500 A BR 0007500A BR 0007500 A BR0007500 A BR 0007500A
Authority
BR
Brazil
Prior art keywords
compound
triazole
drug
dopamine receptor
compounds
Prior art date
Application number
BR0007500-0A
Other languages
English (en)
Inventor
Dorothea Starck
Hans-Joerg Treiber
Liliane Unger
Barbara Neumann-Schultz
Kai Blumbach
Dietmar Sch Bel
Original Assignee
Basf Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Basf Ag filed Critical Basf Ag
Publication of BR0007500A publication Critical patent/BR0007500A/pt

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/10—Drugs for genital or sexual disorders; Contraceptives for impotence
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/08—Antiepileptics; Anticonvulsants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/20—Hypnotics; Sedatives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/22—Anxiolytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A61P25/32—Alcohol-abuse
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A61P25/34—Tobacco-abuse
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A61P25/36—Opioid-abuse
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D249/00—Heterocyclic compounds containing five-membered rings having three nitrogen atoms as the only ring hetero atoms
    • C07D249/02—Heterocyclic compounds containing five-membered rings having three nitrogen atoms as the only ring hetero atoms not condensed with other rings
    • C07D249/08—1,2,4-Triazoles; Hydrogenated 1,2,4-triazoles
    • C07D249/10—1,2,4-Triazoles; Hydrogenated 1,2,4-triazoles with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D249/12—Oxygen or sulfur atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/06—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
    • C07D405/06—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
    • C07D409/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings
    • C07D409/04—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
    • C07D409/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
    • C07D417/04—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D491/00—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
    • C07D491/02—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains two hetero rings
    • C07D491/04—Ortho-condensed systems

Abstract

"COMPOSTO TRIAZOL, FáRMACO, E, USO DO COMPOSTO". A invenção refere-se a compostos triazol de fórmula (I) em que R^ 1^, R^ 2^, A e B tem os significados dados na descrição. Os compostos providos para a invenção tem uma alta afinidade para receptor de dopamina D~ 3~ e são, assim, apropriados para o tratamento de doenças que respondem à influência de ligandos de receptor de dopamina D~ 3~.
BR0007500-0A 1999-01-12 2000-01-12 Composto triazol, fármaco, e, uso do composto BR0007500A (pt)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
DE19900811 1999-01-12
PCT/EP2000/000177 WO2000042036A1 (de) 1999-01-12 2000-01-12 Triazolverbindungen mit dopamin-d3-rezeptoraffinität

Publications (1)

Publication Number Publication Date
BR0007500A true BR0007500A (pt) 2001-10-23

Family

ID=7894006

Family Applications (2)

Application Number Title Priority Date Filing Date
BR0007500-0A BR0007500A (pt) 1999-01-12 2000-01-12 Composto triazol, fármaco, e, uso do composto
BR0007504-3A BR0007504A (pt) 1999-01-12 2000-01-12 Composto triazol, fármaco, e, uso de pelo menos um composto

Family Applications After (1)

Application Number Title Priority Date Filing Date
BR0007504-3A BR0007504A (pt) 1999-01-12 2000-01-12 Composto triazol, fármaco, e, uso de pelo menos um composto

Country Status (28)

Country Link
US (3) US6602867B1 (pt)
EP (3) EP1144405B1 (pt)
JP (3) JP2002534521A (pt)
KR (3) KR100730667B1 (pt)
CN (3) CN1267430C (pt)
AR (3) AR022230A1 (pt)
AT (3) ATE366729T1 (pt)
AU (3) AU2289700A (pt)
BG (2) BG65086B1 (pt)
BR (2) BR0007500A (pt)
CA (3) CA2359952A1 (pt)
CO (3) CO5150182A1 (pt)
CZ (2) CZ20012550A3 (pt)
DE (3) DE50014472D1 (pt)
ES (2) ES2334326T3 (pt)
HK (1) HK1045311B (pt)
HR (1) HRP20010590A2 (pt)
HU (2) HUP0200709A3 (pt)
ID (2) ID29930A (pt)
IL (3) IL144137A0 (pt)
NO (2) NO20013444L (pt)
NZ (2) NZ512864A (pt)
PL (2) PL201889B1 (pt)
SK (2) SK9852001A3 (pt)
TR (2) TR200102025T2 (pt)
TW (1) TWI274750B (pt)
WO (3) WO2000042036A1 (pt)
ZA (2) ZA200106585B (pt)

Families Citing this family (53)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB9810876D0 (en) 1998-05-20 1998-07-22 Smithkline Beecham Plc Compounds
US6605607B1 (en) 1998-10-08 2003-08-12 Smithkline Beecham P.L.C. Tetrahydrobenzazepine derivatives useful as modulators of dopamine D3 receptors (antipsychotic agents)
AR022230A1 (es) 1999-01-12 2002-09-04 Abbott Gmbh & Co Kg Compuestos de triazol, composicion farmaceutica que los comprende y uso de los mismos para preparar dicha composicion
US7229986B2 (en) * 2000-05-16 2007-06-12 Takeda Pharmaceutical Company Ltd. Melanin-concentrating hormone antagonist
MXPA03004243A (es) * 2000-11-14 2004-03-16 Smithkline Beecham Plc Derivados de tetrahidrobenzazepina utiles como moduladores de receptores de dopamina d3 (agentes antipsicoticos).
HU227543B1 (en) * 2001-09-28 2011-08-29 Richter Gedeon Nyrt N-[4-(2-piperazin- and 2-piperidin-1-yl-ethyl)-cyclohexyl]-sulfon- and sulfamides, process for their preparation, their use and pharmaceutical compositions containing them
GB0130219D0 (en) * 2001-12-18 2002-02-06 Pfizer Ltd Compounds for the treatment of sexual dysfunction
US20050176759A1 (en) * 2001-12-21 2005-08-11 Mahmood Ahmed 7-sulfonyl-3-benzazepine derivatives as modulators of the dopamine receptor and their use for the treatment cns disorders
US7314937B2 (en) * 2002-03-21 2008-01-01 Eli Lilly And Company Non-imidazole aryl alkylamines compounds as histamine H3 receptor antagonists, preparation and therapeutic uses
MY133587A (en) 2002-05-29 2007-11-30 Glaxo Group Ltd Aromatic sulfones and their medical use
DE10304870A1 (de) * 2003-02-06 2004-08-19 Abbott Gmbh & Co. Kg Triazolverbindungen und ihre therapeutische Verwendung
DE602004014261D1 (de) * 2003-03-17 2008-07-17 Bayer Healthcare Ag Diagnostik- und therapie- verfahren von mit dopaminrezeptor d3 (drd3) verbundenen krankheiten
US6919342B2 (en) 2003-06-05 2005-07-19 Abbott Gmbh & Co. Kg Triazole compounds suitable for treating disorders that respond to modulation of the dopamine D3 receptor
US20080207685A1 (en) * 2003-11-20 2008-08-28 Eli Lilly And Company Heterocyclic Compounds As Modulators Of Peroxisome Proliferator Activated Receptors, Useful For The Treatment And/Or Prevention Of Disorders Modulated By A Ppar
KR20050054084A (ko) * 2003-12-03 2005-06-10 한국전자통신연구원 수신 환경에 기반한 위성 상태 데이터 분배 기능을 가지는위성관제 시스템 및 그 방법
SI2060570T1 (sl) * 2004-02-23 2012-05-31 Glaxo Group Ltd Derivati azabiciklo o heksana uporabni kot modulatorji dopaminskih receptorjev d
EP1737851A1 (en) * 2004-03-08 2007-01-03 Glaxo Group Limited Tetrahydrobenzazepine derivatives as modulators of dopamine d3 receptors (antipsychotic agents)
US7563905B2 (en) * 2004-03-12 2009-07-21 Wyeth Triazole derivatives and method of using the same to treat HIV infections
GB0412314D0 (en) * 2004-06-02 2004-07-07 Glaxo Group Ltd Compounds
DE102004027358A1 (de) 2004-06-04 2005-12-29 Abbott Gmbh & Co. Kg Pyrimidinverbindungen und ihre Verwendung
GB0413879D0 (en) * 2004-06-21 2004-07-21 Glaxo Group Ltd Compounds
GB0414795D0 (en) * 2004-07-01 2004-08-04 Glaxo Group Ltd Compounds
DE602005018366D1 (de) 2004-08-09 2010-01-28 Abbott Gmbh & Co Kg Zur behandlung von auf eine modulation des dopamin-d3-rezeptors ansprechende erkrankungen geeignete 4-piperazinylpyrimidinverbindungen
EP1784390A2 (en) * 2004-08-13 2007-05-16 Amgen Inc. Substituted benzofused heterocycles
ES2417488T3 (es) 2004-12-02 2013-08-08 Abbott Gmbh & Co. Kg Compuestos de triazol adecuados para tratar trastornos que responden a la modulación del receptor de dopamina D3
GB0507602D0 (en) * 2005-04-14 2005-05-18 Glaxo Group Ltd Compounds
GB0507680D0 (en) * 2005-04-15 2005-05-25 Glaxo Group Ltd Compounds
JP5068747B2 (ja) * 2005-06-14 2012-11-07 グラクソ グループ リミテッド ドーパミンｄ３受容体のモジュレーターとしてのアザビシクロ［３．１．０］ヘキサン誘導体
JP5118039B2 (ja) 2005-08-18 2013-01-16 シンタ ファーマシューティカルズ コーポレーション Ｈｓｐ９０活性を調節するトリアゾール化合物
WO2007022933A1 (en) * 2005-08-22 2007-03-01 Glaxo Group Limited Triazole derivatives as modulators of dopamine d3 receptors
WO2007028145A2 (en) * 2005-09-02 2007-03-08 Dara Biosciences, Inc. Agents and methods for reducing protein tyrosine phosphatase 1b activity in the central nervous system
US20070293548A1 (en) * 2006-03-31 2007-12-20 Wang Eric Y Inhibitors of semicarbazide-sensitive amine oxidase (SSAO) and VAP-1 mediated adhesion useful for treatment and prevention of diseases
MX2009008547A (es) 2007-02-08 2010-01-15 Synta Pharmaceuticals Corp Compuestos de triazol que son utiles en el tratamiento de trastornos proliferativos tales como cancer.
TW201011003A (en) * 2008-08-08 2010-03-16 Synta Pharmaceuticals Corp Triazole compounds that modulate HSP90 activity
CN102264733B (zh) 2008-10-10 2014-07-30 中国人民解放军军事医学科学院毒物药物研究所 新型多巴胺d3受体配体，其制备方法及其医药用途
US9227944B2 (en) 2008-10-10 2016-01-05 Institute Of Pharmacology And Toxicology Academy Of Military Science P.L.A. China Dopamine D3 receptor ligands and preparation and medical uses of the same
US9326955B2 (en) * 2008-10-31 2016-05-03 Loyola University Chicago Combination pharmaceuticals and methods thereof using proteinacious channels as treatments for medical conditions
WO2011087713A2 (en) * 2009-12-22 2011-07-21 Cephalon, Inc. Tricyclic derivatives and their pharmaceutical use and compositions
US9035059B2 (en) * 2011-03-14 2015-05-19 Taisho Pharmaceutical Co., Ltd. Nitrogen-containing condensed heterocyclic compound
JP5992096B2 (ja) * 2012-05-30 2016-09-14 エフ．ホフマン−ラ ロシュ アーゲーＦ． Ｈｏｆｆｍａｎｎ−Ｌａ Ｒｏｃｈｅ Ａｋｔｉｅｎｇｅｓｅｌｌｓｃｈａｆｔ Ｐｄｅ１０阻害剤としてのトリアゾロ化合物
RU2561063C1 (ru) * 2014-07-01 2015-08-20 Общество с ограниченной ответственностью "Научно-производственное объединение "Фарматрон" (НПО "Фарматрон") Способ коррекции неврологических нарушений при хронической алкогольной интоксикации
GB201415573D0 (en) 2014-09-03 2014-10-15 Cancer Therapeutics Crc Pty Ltd Compounds
US10494376B2 (en) 2014-09-03 2019-12-03 Ctxt Pty. Ltd. Tetrahydroisoquinoline derived PRMT5-inhibitors
WO2016034671A1 (en) 2014-09-03 2016-03-10 Ctxt Pty Ltd Aminoindane-, aminotetrahydronaphthalene- and aminobenzocyclobutane-derived prmt5-inhibitors
GB201604030D0 (en) 2016-03-09 2016-04-20 Ctxt Pty Ltd Compounds
GB201604020D0 (en) 2016-03-09 2016-04-20 Ctxt Pty Ltd Compounds
GB201604031D0 (en) 2016-03-09 2016-04-20 Ctxt Pty Ltd Compounds
GB201604022D0 (en) 2016-03-09 2016-04-20 Ctxt Pty Ltd Compounds
GB201604027D0 (en) 2016-03-09 2016-04-20 Ctxt Pty Ltd Compounds
GB201604029D0 (en) 2016-03-09 2016-04-20 Ctxt Pty Ltd Compounds
US11136312B2 (en) * 2017-05-12 2021-10-05 Board of Trustees of the Southern Illinois University 3,4,5-trisubstituted-1,2,4-triazoles and 3,4,5-trisubstituted-3-thio-1,2,4-triazoles and uses thereof
US10941153B2 (en) * 2018-05-31 2021-03-09 Regents Of The University Of Minnesota Substituted phenethylamine derivatives
GB202117129D0 (en) * 2021-11-26 2022-01-12 Epidarex Exeed Ltd Compounds

Family Cites Families (35)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4338453A (en) 1980-09-17 1982-07-06 The Upjohn Company Aminoalkyl-1,2,4-triazoles
US4408049A (en) 1980-09-17 1983-10-04 The Upjohn Company Substituted piperazinyl-1,2,4-triazoles
US4577020A (en) * 1983-01-25 1986-03-18 The Upjohn Company Aminoalkyl and aminoalkenyl triazoles as anti-psychotic agents
FR2601952B1 (fr) * 1986-07-23 1988-11-25 Carpibem Nouveaux derives amino alkyl thio de triazolopyridine ou triazoloquinoline, leurs procedes de preparation, medicaments les contenant, utiles notamment comme antalgiques
AU644500B2 (en) * 1990-12-20 1993-12-09 Merrell Dow Pharmaceuticals Inc. 3-aryl-5-alkylthio-4h-1,2,4-triazoles for treatment of hyperreflexia due to spinal trauma
JP3155276B2 (ja) 1991-05-20 2001-04-09 ファルマシア・アンド・アップジョン・カンパニー カルボキサミド−（１，２ｎ）−カルボサイクリック−２−アミノテトラリン誘導体
AU669866B2 (en) 1991-11-05 1996-06-27 Smithkline Beecham Corporation Endothelin receptor antagonists
FR2687146B1 (fr) 1992-02-12 1994-04-01 Adir Cie Nouveaux derives de pyrrolidine, leur procede de preparation et les compositions pharmaceutiques qui les contiennent.
MA23172A1 (fr) 1993-04-27 1994-12-31 Smithkline Beecham Corp Antagonistes de recepteurs d'endotheline .
DE4338396A1 (de) * 1993-11-10 1995-05-11 Basf Ag N-Substituierte Azabicycloalkan-Derivate, ihre Herstellung und Verwendung
FR2722194B1 (fr) 1994-07-06 1996-08-23 Adir Nouveaux derives de benzopyrane, leur procede de preparation et les compositions pharmacuetiques qui les contiennent
DE4425144A1 (de) 1994-07-15 1996-01-18 Basf Ag Triazolverbindungen und deren Verwendung
BR9509760A (pt) * 1994-11-23 1998-06-30 Neurogen Corp Composto
WO1996030333A1 (en) 1995-03-27 1996-10-03 Smithkline Beecham Plc Bicyclic amine derivatives and their use as anti-psychotic agents
WO1996031512A1 (en) * 1995-04-06 1996-10-10 Novo Nordisk A/S Benzopyranopyrrole compounds, their preparation and use
GB9518572D0 (en) 1995-09-12 1995-11-15 Smithkline Beecham Plc Compounds
AU7490496A (en) * 1995-11-10 1997-05-29 Novo Nordisk A/S Enantiomers of cis-benz{e}indole compounds, their preparation and utility as dopamine-d3 receptor selective agents
FR2742149B1 (fr) 1995-12-11 1998-02-13 Inst Nat Sante Rech Med Nouveaux derives de 2-naphtamides et leurs applications therapeutiques
DE19600934A1 (de) * 1996-01-12 1997-07-17 Basf Ag Substituierte Aza- und Diazacycloheptan- und Cyclooctanverbindungen und deren Verwendung
US5688950A (en) 1996-04-23 1997-11-18 Neurogen Corporation Tricyclic aminoalkylcarboxamides; novel dopamine D3 receptor subtype specific ligands
WO1997043262A1 (en) 1996-05-11 1997-11-20 Smithkline Beecham P.L.C. Tetrahydroisoquinoline derivatives as modulators of dopamine d3 receptors
AU720414B2 (en) * 1996-05-31 2000-06-01 Pharmacia & Upjohn Company Aryl substituted cyclic amines as selective dopamine D3 ligands
GB9612153D0 (en) 1996-06-11 1996-08-14 Smithkline Beecham Plc Compounds
AU4204697A (en) * 1996-08-14 1998-03-06 Smithkline Beecham Plc Tetrahydroisoquinoline derivatives and their pharmaceutical use
JPH10195056A (ja) * 1996-11-12 1998-07-28 Takeda Chem Ind Ltd 縮合ベンゼン誘導体、その製造法および剤
DK0942911T3 (da) 1996-12-06 2002-12-02 Abbott Lab Benzopyranopyrroler og benzopyranopyridiner med alfa-1-adrenerg virkning
FR2760014B1 (fr) * 1997-02-27 1999-04-09 Adir Nouveaux composes de 2-amino indane, leur procede de preparation et les compositions pharmaceutiques qui les contiennent
GB9708694D0 (en) * 1997-04-30 1997-06-18 Smithkline Beecham Plc Compounds
GB9708805D0 (en) * 1997-05-01 1997-06-25 Smithkline Beecham Plc Compounds
HUP0003608A3 (en) * 1997-05-03 2001-06-28 Smithkline Beecham Plc Tetrahydroisoquinoline derivatives, process for producing them and pharmaceutical compositions containing them
GB9709303D0 (en) 1997-05-09 1997-06-25 Smithkline Beecham Plc Compounds
GB9710366D0 (en) * 1997-05-20 1997-07-16 Biocompatibles Ltd Stent deployment device
FR2764890B1 (fr) * 1997-06-24 1999-08-27 Adir Nouveaux derives chromeniques, leur procede de preparation et les compositions pharmaceutiques qui les contiennent
DE19728996A1 (de) 1997-07-07 1999-01-14 Basf Ag Triazolverbindungen und deren Verwendung
AR022230A1 (es) 1999-01-12 2002-09-04 Abbott Gmbh & Co Kg Compuestos de triazol, composicion farmaceutica que los comprende y uso de los mismos para preparar dicha composicion

Also Published As

Publication number Publication date
BR0007504A (pt) 2001-10-02
ATE424398T1 (de) 2009-03-15
TR200102025T2 (tr) 2002-05-21
CZ20012551A3 (cs) 2002-03-13
US6583166B1 (en) 2003-06-24
US6579892B1 (en) 2003-06-17
PL349841A1 (en) 2002-09-23
KR20070032830A (ko) 2007-03-22
WO2000042036A1 (de) 2000-07-20
JP4615125B2 (ja) 2011-01-19
US6602867B1 (en) 2003-08-05
HK1045311A1 (en) 2002-11-22
PL201889B1 (pl) 2009-05-29
CN1345318A (zh) 2002-04-17
HRP20010590A2 (en) 2003-08-31
SK9862001A3 (en) 2002-04-04
NO20013443D0 (no) 2001-07-11
CA2359952A1 (en) 2000-07-20
IL144136A0 (en) 2002-05-23
TR200102026T2 (tr) 2001-12-21
BG65086B1 (bg) 2007-02-28
NO20013444D0 (no) 2001-07-11
AU773047B2 (en) 2004-05-13
TWI274750B (en) 2007-03-01
DE50014472D1 (de) 2007-08-23
BG65105B1 (bg) 2007-02-28
JP2002534520A (ja) 2002-10-15
CA2359942A1 (en) 2000-07-20
PL350246A1 (en) 2002-12-02
EP1144405B1 (de) 2009-11-25
KR100687682B1 (ko) 2007-02-28
ES2288839T3 (es) 2008-02-01
CO5150227A1 (es) 2002-04-29
KR20010086470A (ko) 2001-09-12
AR022228A1 (es) 2002-09-04
KR100775720B1 (ko) 2007-11-09
AU2289700A (en) 2000-08-01
NO20013444L (no) 2001-07-11
HUP0200522A3 (en) 2003-05-28
HK1045311B (zh) 2007-03-30
AR022229A1 (es) 2002-09-04
AU772948B2 (en) 2004-05-13
CN1345319A (zh) 2002-04-17
WO2000042037A1 (de) 2000-07-20
PL200238B1 (pl) 2008-12-31
CA2359948A1 (en) 2000-07-20
EP1144405A1 (de) 2001-10-17
HUP0200709A2 (hu) 2002-07-29
ES2334326T3 (es) 2010-03-09
AR022230A1 (es) 2002-09-04
CO5150224A1 (es) 2002-04-29
AU2541200A (en) 2000-08-01
EP1140908B1 (de) 2009-03-04
KR100730667B1 (ko) 2007-06-21
CN1267430C (zh) 2006-08-02
CN1347414A (zh) 2002-05-01
JP2002534521A (ja) 2002-10-15
WO2000042038A1 (de) 2000-07-20
ATE366729T1 (de) 2007-08-15
EP1140907B1 (de) 2007-07-11
EP1140908A1 (de) 2001-10-10
DE50015802D1 (de) 2010-01-07
IL144136A (en) 2006-12-10
JP2002534519A (ja) 2002-10-15
ZA200106585B (en) 2002-08-12
JP4933694B2 (ja) 2012-05-16
NO20013443L (no) 2001-07-12
HUP0200709A3 (en) 2004-07-28
IL144137A0 (en) 2002-05-23
KR20010086471A (ko) 2001-09-12
NZ512864A (en) 2003-04-29
DE50015576D1 (de) 2009-04-16
ZA200106584B (en) 2002-08-12
CO5150182A1 (es) 2002-04-29
ATE449768T1 (de) 2009-12-15
CN1149209C (zh) 2004-05-12
ID29552A (id) 2001-09-06
AU2436700A (en) 2000-08-01
SK9852001A3 (en) 2002-04-04
EP1140907A1 (de) 2001-10-10
BG105784A (en) 2002-02-28
CA2359948C (en) 2010-09-21
CZ20012550A3 (cs) 2002-02-13
CZ303926B6 (cs) 2013-06-26
BG105783A (en) 2002-03-29
ID29930A (id) 2001-10-25
NZ512830A (en) 2003-08-29
HUP0200522A2 (en) 2002-06-29

Similar Documents

Publication Publication Date Title
BR0007500A (pt) Composto triazol, fármaco, e, uso do composto
BR9810984A (pt) Composto de triazol, uso do mesmo, e, composição farmacêutica
ATE242783T1 (de) Glycopeptid-derivate und pharmazeutische zusammensetzungen, die sie enthalten
BR0312464A (pt) Inibidores de tirosina quinases
BR0112030A (pt) Novos compostos que possuem atividade antibacteriana, antifúngica ou antitumor
BR9911488A (pt) Composto, uso do mesmo, composição farmacêutica, e, processos para tratamento ou de profilaxia de doenças inflamatórias, e para a preparação de um composto
BR9911482A (pt) Composto, composição farmacêutica, uso do composto, e, processos para o tratamento ou profilaxia de doenças inflamatórias, e para a preparação de um composto
BR0206955A (pt) Ligantes de receptores de canabinóides
TR200103186T2 (tr) MEK enzimlerinin inhibitörleri olarak kinolin türevleri
BR9812492A (pt) Composto, uso do mesmo, formulação farmacêutica, e, processos para o tratamento de uma doença cardiovascular, para o tratamento de uma vasoconstrição, e para a preparação de compostos
BR0107628A (pt) l,2-diarilbenzimidazóis para tratamento de doenças que estão associadas a uma ativação microglial
BR0109542A (pt) Derivados de imidazopirina alquilados
TR200000737T2 (tr) İkame edilmiş kroman türevleri.
NO971997D0 (no) Bruk av immunmodulerende midler
BR9813719A (pt) Agentes terapêuticos
DE59108770D1 (de) Fluorverbindungen als Aromatase-Inhibitoren
DE59108566D1 (de) Heteroarylmethylbenzole-Aromatasehemmer
DE69827614D1 (de) Chinoxalindionen
UY27372A1 (es) Derivados de bencimidazol 1-aril-2-n, s u o-sustituidos, su uso para la obtención de medicamentos y preparados farmacéuticos que contienen estos derivados
TW371661B (en) Novel intermediates and their use to prepare N,N'-bridged bisindolylmaleimides
BR0312719A (pt) Compostos, processos de obtenção de carbamatos e de derivados n-fosforilados e de derivados de amidoxima, composições farmacêuticas, e, utilização de pelo menos um composto
BR0012592A (pt) Composto, uso dos compostos, combinação, e, preparação farmacêutica para uso oral ou parenteral
RS50412B (sr) Derivati tiazofurina
BR9915898A (pt) Compostos, composição farmacêutica, e, utilização de um composto
TH57990B (th) อนุพันธ์ของไกลโคเพปไทด์และองค์ประกอบทางเภสัชกรรมซึ่งมีสารชนิดเดียวกัน

Legal Events

Date Code Title Description
B07A Application suspended after technical examination (opinion) [chapter 7.1 patent gazette]
B09B Patent application refused [chapter 9.2 patent gazette]

Free format text: INDEFIRO O PEDIDO DE ACORDO COM O(S) ARTIGO(S) 8O, 13, 24 E 25 DA LPI

B12B Appeal against refusal [chapter 12.2 patent gazette]